RxDoctor Payments Data

Aaron Compton, MD

Interventional Pain Medicine · Louisville, KYNPI 1609918879

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,487 of the $2,799 with a category attached, or 88.9%. Abbott accounts for 60.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2020 at $714 and has fallen 59.5% since, to $289 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in KY, where the typical reported total is $3,169.

$2,799in general payments, 2019–2025

Across 97 payments — averaging $28.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Nevro Corp.$224
  • Boston Scientific$211
  • Si-bone, Inc.$174
  • Stryker$125
  • Vertex$72
  • plus $304 from 11 others

What the payments were for

  • Food & beverage$2,48789%
  • Education$31111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,799 in reported general payments places this provider in the 45th percentile of 55 interventional pain medicine providers in Kentucky.

See all interventional pain medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$648,356
Medicare patients
706
Services billed
11,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl13$10,271
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen721$9,457
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen466$9,210
MovantikNaloxegol Oxalate12$6,904
Gabapentin512$5,995
Buprenorphine15$4,363
Pregabalin77$2,395
Tramadol Hcl426$1,904
Lidocaine12$1,363
Meloxicam97$981
Tizanidine Hcl143$845
Morphine Sulfate ErMorphine Sulfate31$752
Oxycodone Hcl38$510
Celecoxib24$500
Acetaminophen-CodeineAcetaminophen With Codeine15$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$29$6,90412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 55 interventional pain medicine providers in Kentucky.

Other interventional pain medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →